Boardroom Alpha
Boardroom Alpha
DMRA · Current Report (Form 8-K) · Filed February 11, 2026

Damora Therapeutics Inc — Current Report (Form 8-K)

Form
8-K
Filed
February 11, 2026
Period
Feb 10, 2026
Ticker
DMRA
Accession
0001193125-26-046817
Boardroom Alpha · Filing insights

Galecto enters underwriting for 14,473,685 shares at $19 with a 30-day option for 2,171,052 more. Option exercised in full; net proceeds about $295.9 million to fund DMR-001 Phase 3; closing expected Feb 12, 2026.

About Damora Therapeutics Inc
Market cap
$1.8B
1Y TSR
+808.0%
3Y TSR
−5.5%
Board grade
B
Sector
Healthcare
CEO
Jennifer Jarrett
Last annual meeting: Jun 17, 2026 · View full Damora Therapeutics Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 10, 2026

 

 

GALECTO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39655   37-1957007

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

75 State Street, Suite 100

Boston, MA 02109

(Address of principal executive offices, including zip code)

(+45) 70 70 52 10

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trade

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share   GLTO   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01.

Entry into a Material Definitive Agreement

On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $19.00 per share. In addition, the Company granted the Underwriters a 30-day option (the “Option”) to purchase up to an additional 2,171,052 shares of its Common Stock on the same terms and conditions as the Common Stock sold in the Offering, which the Underwriters exercised in full on February 11, 2026.

The net proceeds to the Company from the Offering are approximately $295.9 million, which includes the proceeds from the exercise of the Option, after deducting underwriting discounts and commissions and estimated offering expenses. The net proceeds of this Offering together with existing cash and cash equivalents are expected to be sufficient to fund operations into Phase 3 development of DMR-001. The Company has based this estimate on assumptions that may prove to be incorrect, and the Company could use its available capital resources sooner than it currently anticipates.

The Common Stock described above was offered pursuant to an automatic shelf registration statement on Form S-3 (File No. 333-293343), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2026 and automatically became effective upon filing. A final prospectus supplement dated February 10, 2026 relating to and describing the terms of the Offering was filed with the SEC on February 11, 2026. The Offering is expected to close on February 12, 2026.

In the Underwriting Agreement, the Company agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the underwriters may be required to make because of such liabilities. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed herewith as Exhibit 1.1 and incorporated by reference herein.

A copy of the opinion of Gibson, Dunn & Crutcher LLP relating to the validity of the shares of Common Stock issued in the Offering is filed herewith as Exhibit 5.1.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit

Number

  

Exhibit Description

1.1    Underwriting Agreement, by and among the Company and Jefferies LLC and Leerink Partners LLC, dated as of February 10, 2026
5.1    Opinion of Gibson, Dunn & Crutcher LLP
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Galecto, Inc.
Date: February 11, 2026     By:  

/s/ Sherwin Sattarzadeh

      Sherwin Sattarzadeh
      Chief Operating Officer
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Damora Therapeutics Inc (DMRA)

Reference

Frequently asked questions

When did Damora Therapeutics Inc file this 8-K?
Damora Therapeutics Inc (DMRA) filed this Current Report (Form 8-K) with the SEC on February 11, 2026. The accession number assigned by EDGAR is 0001193125-26-046817.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Galecto enters underwriting for 14,473,685 shares at $19 with a 30-day option for 2,171,052 more. Option exercised in full; net proceeds about $295.9 million to fund DMR-001 Phase 3; closing expected Feb 12, 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Damora Therapeutics Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Damora Therapeutics Inc has filed under CIK 1800315, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer